TO ALL MULTIPLE SCLEROSIS PATIENTS:

https://multiplesclerosisnewstoday.com/news-posts/2019/05/17/ms-news-caught-eye-biomarker-rrms-treatment-ocrevus-costs-meds/

https://medicalxpress.com/news/2019-05-culprit-multiple-sclerosis-relapses.amp

https://amp.theguardian.com/society/2019/may/09/new-drug-for-multiple-sclerosis-patients-after-maker-drops-price

https://www.nytimes.com/2019/05/01/magazine/symptoms-multiple-sclerosis-diagnosis.html

https://medicalxpress.com/news/2019-05-statins-potential-multiple-sclerosis-unrelated.amp

https://multiplesclerosisnewstoday.com/news-posts/2019/05/10/lyfebulb-and-celgene-announce-finalists-for-2019-addressing-unmet-needs-in-ms-an-innovation-challenge/

https://multiplesclerosisnewstoday.com/news-posts/2019/05/09/good-news-nice-approves-ocrevus-ocrelizumab-for-primary-progressive-ms/

https://multiplesclerosisnewstoday.com/news-posts/2019/05/07/need-to-know-what-is-dysarthria/

GET MOBILE MS CLINICS SET UP IN THE WORLD, TO SWITCH ALL MS PATIENTS ONTO THE NEWER MEDICATIONS.

75 MG OF EVOBRUTINIB, ONCE DAILY IS BEST TOO :

https://www.ajmc.com/newsroom/evobrutinib-reduced-signs-of-active-inflammatio-in-patients-with-multiple-sclerosis

https://multiplesclerosisnewstoday.com/news-posts/2019/05/16/aanam-positive-phase-ii-data-further-highlights-clinical-proof-of-concept-for-evobrutinib-first-oral-brutons-tyrosine-kinase-btk-inhibitor-to-report-positive-phase-ii-clinical-results-in/

TRY OCREVUS TOO :

https://multiplesclerosisnewstoday.com/news-posts/2019/04/15/aan2019-pharmacokinetics-pharmacodynamics-and-exposure-response-analyses-of-ocrelizumab-in-patients-with-multiple-sclerosis/

https://www.neurologyadvisor.com/conference-highlights/aan-2019-conference/ocrelizumab-demonstrates-sustained-benefit-on-disability-progression-in-ms/

80 MG/DAY OF SIMVASTATIN IS NECESSARY TOO :

https://www.specialtypharmacytimes.com/news/statin-benefit-in-multiple-sclerosis-not-due-to-cholesterol-lowering-effects

GET RITUXIMAB FOR ALL MS PATIENTS TOO :

https://www.empr.com/home/mpr-first-report/aan-2019-coverage/rituximab-related-serious-infections-unlikely-in-multiple-sclerosis/

GET ALL MS PATIENTS ONTO FIBRINOGEN BLOCKERS/INHIBITORS  :

https://multiplesclerosisnewstoday.com/news-posts/2019/05/09/a-new-culprit-for-multiple-sclerosis-relapses/

TRY CHROMATIN MODIFICATION ENZYME INHIBITORS TOO :

https://www.sciencedaily.com/releases/2019/05/190510091354.htm

ATTEMPT BTK BLOCKERS, OR THE SAR442168 :

https://multiplesclerosisnewstoday.com/news-posts/2019/05/15/principia-biopharma-announces-first-patient-dosed-in-sanofis-phase-2b-trial-of-sar442168-in-multiple-sclerosis-triggering-30-million-milestone/


ESTRIOL THERAPY IS NECESSARY TOO :

https://dailybruin.com/2019/05/15/ucla-researchers-work-to-advance-treatment-targeting-source-of-multiple-sclerosis/

BRING ALL OF THE MS PATIENTS TO NEUROLOGISTS, AND UROLOGISTS, TO GET THEM ONTO FLOMAX, OR SOMETHING SAFER, HIGHER-TECH, IF THEY HAVE URINARY RETENTION TOO.

TREAT THEM ONCE PER WEEK, PROPHYLACTICALLY, FOR URINARY TRACT INFECTIONS TOO.